ERIN MCKEON

FY 2026 Funding for medical research at the NIH and CDC FY 2026 Appropriations - DoD Congressionally Directed Medical Research Program Help Ensure Lower Patient Copays Act Accelerating Kids Access to Care Act Pharmacy Benefit Manager Transparency Act Reauthorization of ACA enhanced advance premium tax credits HR 5509 / S 2903: Safe Step Act CMS - ACA Marketplace Integrity and Affordability Rule CMS - Reimbursement for infused biosimilars CMS - Medicare Competitive bidding for ostomy supplies FDA - Approvals for pediatric IBD medications HHS - FY 2027 NBPP

Increasing access to care by limiting step therapy. Safe Step Act HR 2630, S 652. Lowering out-of-pocket costs for patients. HELP Copays Act HR830, S1375 HHS response to HIV+Hep vs Baccerra law suit. FY 2026 HHS Notice of Benefit Payments and Parameters, copay assistance. Pharmacy Benefit Manager Reform. PBM Transparency Act S 127; Prescription Pricing for the People Act S 113; PBM Reform Act, S. 1339; Hidden Fee Disclosure Act HR 4508. Funding for medical research and education at the NIH and CDC. Biosimliar interchageability. HHS rule on Section 1557 of the Affordable Care Act (ACA) that will strengthen non-discrimination protections in health care. Fifth Circuits decision in Alliance for Hippocratic Medicine et al. v FDA et al. Committee on Education and Workforce ERISA RFI: step therapy reform, copay accumulators and maximizers. FDA - proposed guidance on Diversity Action Plans for medical clinical trials; proposed guidance on development of medications for pediatric inflamatory bowel disease patients.

HHS FY 2025 NBPP, as relates to copay accumulators. Enforcement of HIV + Hep, et al vs. Becerra.

Increasing access to care by limiting step therapy. Safe Step Act HR 2630, S 652. Lowering out-of-pocket costs for patients. HELP Copays Act HR830, S1375 HHS response to HIV+Hep vs Baccerra law suit. FY 2025 HHS Notice of Benefit Payments and Parameters, copay assistance. Pharmacy Benefit Manager Reform. PBM Transparency Act S 127; Prescription Pricing for the People Act S 113; PBM Reform Act, S. 1339; Hidden Fee Disclosure Act HR 4508. Funding for medical research and education at the NIH and CDC. Biosimliar interchageability. HHS rule on Section 1557 of the Affordable Care Act (ACA) that will strengthen non-discrimination protections in health care. Fifth Circuits decision in Alliance for Hippocratic Medicine et al. v FDA et al. Committee on Education and Workforce ERISA RFI: step therapy reform, copay accumulators and maximizers.

HHS FY 2025 NBPP, as relates to copay accumulators.

Increasing access to care by limiting step therapy. Safe Step Act HR 2630, S 652. Lowering out-of-pocket costs for patients. HELP Copays Act HR830, S1375 HHS response to HIV+Hep vs Baccerra law suit. FY 2025 HHS Notice of Benefit Payments and Parameters, copay assistance. Pharmacy Benefit Manager Reform. PBM Transparency Act S 127; Prescription Pricing for the People Act S 113; PBM Reform Act, S. 1339; Hidden Fee Disclosure Act HR 4508. Funding for medical research and education at the NIH and CDC. NIH OADR RFI response. Biosimliar interchageability.